Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Lapatinib is widely used in the later lines treatment of HER2 positive metastatic breast cancer (MBC). EGF104900 study suggested that among patients who experienced progression on prior trastuzumab‐containing regimens, lapatinib plus trastuzumab had better effects than trastuzumab alone. However, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yizhao, Ge, Rui, Sang, Die, Luo, Ting, Li, Wei, Ji, Xuening, Yuan, Peng, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196046/
https://www.ncbi.nlm.nih.gov/pubmed/32108439
http://dx.doi.org/10.1002/cam4.2943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196046/
https://www.ncbi.nlm.nih.gov/pubmed/32108439
http://dx.doi.org/10.1002/cam4.2943

Ejemplares similares